ALLO
Jefferies says the payoff got a little more believable
Allogene Therapeutics is getting another vote of confidence, this time from Jefferies, which raised its price target on the stock to $10 from $6 and kept the Buy rating in place. The new target implies a lot more upside from the current share price around $2.02, which is a pretty dramatic way of saying, “Yes, this biotech still has drama, but maybe now it has a better script.”
Why the Street is leaning in
The call isn’t happening in a vacuum. Jefferies pointed to the company’s recent data readout, saying it helped de-risk the story. In biotech, that’s the difference between “promising science” and “maybe this thing doesn’t blow up on the way to commercialization.” Investors care because every clean readout can improve the odds that the next catalyst — like event-free survival data — lands with a bigger splash.
The Allogene roller coaster continues
This is also a reminder that ALLO has been trading like a biotech soap opera lately. The stock has already been getting a boost from recent cema-cel trial updates, and now the analyst crowd is essentially saying the momentum may not be done yet.
A few moving parts to keep an eye on:
- more analyst follow-through if the data keeps holding up
- whether upcoming event-free survival updates keep the bulls happy
- how much of the upside story is already baked into the stock after the recent pop
Big picture
For long-suffering biotech investors, this is the kind of note that can help keep sentiment warm while the company marches toward its next data checkpoint. The science still has to do the heavy lifting, but for now, Wall Street just handed Allogene a slightly taller ladder.